{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:27Z","timestamp":1794978687506,"version":"4.9.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Teclistamab and other B-cell maturation antigen (BCMA)\u2013targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received once-weekly teclistamab 1.5\u00a0mg\/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex\u00a0vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed\/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6\u00a0months: 5.3% with IVIG vs 54.8% with observation only [P\u00a0&amp;lt; .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #NCT04557098.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011658","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T22:06:32Z","timestamp":1701813992000},"page":"194-206","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":112,"title":["Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation"],"prefix":"10.1182","volume":"8","author":[{"given":"Kristine A.","family":"Frerichs","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie P. M.","family":"Verkleij","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"3University Hospital of Salamanca\/IBSAL\/CIC\/CIBERONC, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"4University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"5Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[{"name":"6Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4904-5050","authenticated-orcid":false,"given":"Alfredo","family":"Perales-Puchalt","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Stephenson","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Uhlar","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-2671","authenticated-orcid":false,"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[{"name":"8HOVON Foundation, Rotterdam, The Netherlands"},{"name":"9Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kruyswijk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Kuipers","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaz","family":"Groen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cortes-Selva","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[{"name":"10Janssen Sciences, Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L.","family":"Zaaijer","sequence":"additional","affiliation":[{"name":"11Department of Medical Microbiology, Amsterdam UMC location, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":false,"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"issue":"6","key":"2024010914090512100_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10396","key":"2024010914090512100_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"16 suppl","key":"2024010914090512100_bib3","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"van de Donk","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024010914090512100_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B cell maturation antigen (BCMA) x CD3 T cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"issue":"31","key":"2024010914090512100_bib5","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A\u00a0phase I first-in-human study of ABBV-383, a B cell maturation antigen\u00a0\u00d7 CD3 bispecific T cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024010914090512100_bib6","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"16 suppl","key":"2024010914090512100_bib7","article-title":"LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16 suppl","key":"2024010914090512100_bib8","article-title":"Elranatamab, a B cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study","volume":"41","author":"Mohty","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024010914090512100_bib9","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024010914090512100_bib10","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","author":"Nooka","year":"14  2023","journal-title":"Cancer"},{"issue":"2","key":"2024010914090512100_bib11","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"2024010914090512100_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clml.2023.03.009","article-title":"Immune reconstitution and vaccinations in multiple myeloma: a report from the 19th International Myeloma Society Annual Workshop","volume":"23","author":"Terpos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024010914090512100_bib13","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024010914090512100_bib14","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024010914090512100_bib15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024010914090512100_bib16","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2024010914090512100_bib17","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"2024010914090512100_bib18","unstructured":"Centers for Disease Control and Prevention\n          . Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 12\u00a0October 2012. Accessed  June 2023. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6140a4.htm."},{"issue":"4","key":"2024010914090512100_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2017.12.795","article-title":"Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance","volume":"24","author":"Palazzo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024010914090512100_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trivac.2013.09.001","article-title":"Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"2","author":"Karlsson","year":"2013","journal-title":"Trials Vaccinol"},{"issue":"5","key":"2024010914090512100_bib21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1128\/CVI.05675-11","article-title":"Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era","volume":"19","author":"Nix","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"2024010914090512100_bib22","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.clml.2020.12.026","article-title":"Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma","volume":"21","author":"Lancman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5425","key":"2024010914090512100_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"issue":"1","key":"2024010914090512100_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2024010914090512100_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-22-0173","article-title":"Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections","volume":"4","author":"Azeem","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"26","key":"2024010914090512100_bib26","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024010914090512100_bib27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.18434","article-title":"Antibody and T cell responses by ultra-deep T cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias","volume":"199","author":"Chung","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2024010914090512100_bib28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood.2021014989","article-title":"Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy","volume":"139","author":"Terpos","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024010914090512100_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ejh.13826","article-title":"Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination","volume":"109","author":"Abdallah","year":"2022","journal-title":"Eur J Haematol"},{"issue":"8","key":"2024010914090512100_bib30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"2024010914090512100_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"2024010914090512100_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2643-3230.BCD-21-0139","article-title":"Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies","volume":"2","author":"Chung","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2024010914090512100_bib33","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/CCM.0000000000001271","article-title":"IV immunoglobulin for acute lung injury and bacteremia in Pseudomonas aeruginosa pneumonia","volume":"44","author":"Katoh","year":"2016","journal-title":"Crit Care Med"},{"issue":"12","key":"2024010914090512100_bib34","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1080\/21645515.2019.1619404","article-title":"Prophylactic and therapeutic protection of human IgG purified from sera containing anti-exotoxin A titers against pneumonia caused by Pseudomonas aeruginosa","volume":"15","author":"Zhang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"2024010914090512100_bib35","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/trf.16938","article-title":"Long-term monitoring of antibody titers against microorganisms in human intravenous immunoglobulin lots derived from healthy donors in Japan manufactured during 1998-2018","volume":"62","author":"Yunoki","year":"2022","journal-title":"Transfusion"},{"issue":"10","key":"2024010914090512100_bib36","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/ajt.17086","article-title":"Intravenous immunoglobulin contains high-titer neutralizing IgG antibodies to SARS-CoV-2","volume":"22","author":"Jordan","year":"2022","journal-title":"Am J Transplant"},{"issue":"1","key":"2024010914090512100_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1473-3099(21)00755-6","article-title":"Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update","volume":"22","author":"Romero","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2024010914090512100_bib38","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024010914090512100_bib39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2024010914090512100_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4161\/mabs.3.4.16092","article-title":"A\u00a0next generation of therapeutic antibodies?","volume":"3","author":"Bakema","year":"2011","journal-title":"MAbs"},{"issue":"suppl 1","key":"2024010914090512100_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B cell maturation antigen (BCMA)-directed therapies: results from Cohort a of the Magnetismm-3 Study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024010914090512100_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2024010914090512100_bib43","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"issue":"42","key":"2024010914090512100_bib44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/EDBK_359656","article-title":"COVID-19 and cancer: special considerations for patients receiving immunotherapy and immunosuppressive cancer therapies","volume":"2022","author":"Goldman","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"77","key":"2024010914090512100_bib45","doi-asserted-by":"crossref","first-page":"eabq7647","DOI":"10.1126\/sciimmunol.abq7647","article-title":"CD8\u00a0T cells contribute to vaccine protection against SARS-CoV-2 in macaques","volume":"7","author":"Liu","year":"2022","journal-title":"Sci Immunol"},{"issue":"7","key":"2024010914090512100_bib46","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2024010914090512100_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/194\/2180522\/blooda_adv-2023-011658-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/194\/2180522\/blooda_adv-2023-011658-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:10:39Z","timestamp":1704809439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/194\/506506\/Teclistamab-impairs-humoral-immunity-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011658","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}